SEC Form 4 · accession 0001144204-18-040074
Bionik Laboratories Corp. · BNKL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andre-Jacques Auberton-Herve
Director · Other
Period of report
Jul 24, 2018
Accepted (ET)
Jul 26, 2018 · 1:55 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001508381
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 24, 2018 | C | 6,688,480 | $0.0513 | A | 21,447,183 | I | Shares held through Star SCI and 4A Consulting & Engineering |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Effective as of July 20, 2018, an aggregate amount of $308,807 in convertible promissory notes issued to Star SCI (the "Notes") converted in accordance with their terms into 6,688,480 shares of the Issuer's common stock. For purposes of the filing of this Form 4, the transaction date is deemed to be July 24, 2018, as that was the date that the Issuer preliminarily determined the number of shares of common stock that the Notes were convertible into in accordance with the terms of the Notes.
- F2The conversion price of the Notes was calculated using the VWAP (as defined in the Notes) average of the last 30 days before July 20, 2018. As of the date hereof, the Issuer has not definitively determined the conversion price. In the event that the Issuer definitively determines that the conversion price was lower than $0.0513, the Reporting Person will file an amendment to this Form 4 to reflect the correct conversion price, number of shares acquired upon conversion, and the amount of securities beneficially owned following the reported transaction.